BIIB
NASDAQBiogen Inc.
SectorHealth CareIndustryBiotechnology: Biological Products (No Diagnostic Substances)
Price$195.30+5.43 (+2.86%)
2026-03-042026-06-05
News · 26 weeks87-60%
2025-12-142026-06-07
Mix4290d
- Other19(45%)
- SEC Filings8(19%)
- Earnings6(14%)
- Analyst4(10%)
- Leadership3(7%)
- Insider2(5%)
Latest news
25 items- SECAmendment: SEC Form SCHEDULE 13G/A filed by Biogen Inc.SCHEDULE 13G/A - BIOGEN INC. (0000875045) (Subject)
- PRBiogen's Salanersen Receives FDA Breakthrough Therapy Designation for Spinal Muscular AtrophyDesignation is supported by an exploratory analysis from the Phase 1b study showing that some children with SMA previously treated with gene therapy who had suboptimal clinical status experienced slowing of neurodegeneration and clinically meaningful improvements in motor function following initiation of salanersenSalanersen is an investigational antisense oligonucleotide dosed once-yearly with the potential to be a meaningful therapy in the future SMA treatment landscape CAMBRIDGE, Mass., June 04, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) announced today that the U.S. Food and Drug Administration (FDA) has granted salanersen Breakthrough Therapy Designation for the treatment o
- PREULAR 2026: Dapirolizumab Pegol Shows Potential to Reduce Flare Rates and Maintain Disease Control in Systemic Lupus ErythematosusSteroid use reduction and disease control: In additional results from the Phase 3 PHOENYCS GO study, dapirolizumab pegol (DZP) plus standard of care was associated with sustained disease control at lower glucocorticoid doses through Week 48 compared with placebo plus standard of care, supporting reduced long-term steroid exposureReduced flare rates and immune marker improvements: In other findings presented at EULAR 2026, improvements in immunological markers and reduced flare rates were observed, supporting the potential of dapirolizumab pegol to address the complex burden of SLE BRUSSELS, Belgium and CAMBRIDGE, Mass., June 04, 2026 (GLOBE NEWSWIRE) -- UCB (Euronext Brussels: UCB) and Bi
- PRBiogen Announces Upcoming Kidney Presentations at European Renal Association and American Transplant CongressesData presentations across multiple kidney diseases illustrate the breadth of Biogen's nephrology portfolio with EMPAVELI® (pegcetacoplan) and felzartamab, an investigational anti-CD38 monoclonal antibody. CAMBRIDGE, Mass., June 03, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) announced that fourteen abstracts highlighting data from its nephrology portfolio, including EMPAVELI® (pegcetacoplan) and investigational felzartamab, have been accepted for presentation at the 63rd European Renal Association Congress (ERA) and the 2026 American Transplant Congress (ATC). "Our presence across two key medical congresses highlights the momentum of our newly broadened nephrology portfolio, which
- PRUCB and Biogen Announce Publication in The Lancet of Positive Dapirolizumab Pegol (DZP) Phase 3 Study Results in Systemic Lupus ErythematosusPublication adds to previously reported findings from Phase 3 PHOENYCS GO study, demonstrating statistically significant improvement in disease activity at Week 48 with dapirolizumab pegol plus standard of care versus placebo plus standard of careFindings showed results in favor of dapirolizumab pegol plus standard of care versus placebo plus standard of care across endpoints, including multiple disease activity measures, severe flares, patient-reported outcomes, including fatigue, and glucocorticoid taperingResults support the continued development of dapirolizumab pegol; the ongoing confirmatory Phase 3 PHOENYCS FLY clinical trial is currently recruiting BRUSSELS, Belgium and CAMBRIDGE, M
- PRStoke Therapeutics to Present at Upcoming Investor Conferences in JuneStoke Therapeutics, Inc. (NASDAQ:STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced that Chief Executive Officer Ian F. Smith and Chief Patient Officer Jason Hoitt will present at the following upcoming investor conferences: 2026 Jefferies Global Healthcare Conference Date: Thursday, June 4, 2026 Time: 9:20 a.m. ET Location: New York, NY Goldman Sachs 47th Annual Global Healthcare Conference 2026 Date: Monday, June 8, 2026 Time: 10:40 a
- PRBiogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson's DiseaseThe Phase 2b LUMA study of BIIB122 in early-stage Parkinson's disease did not meet its primary or secondary endpoints Based on data from the Phase 2b LUMA study, Biogen and Denali will discontinue development of BIIB122 in idiopathic Parkinson's diseaseDenali continues to independently conduct the Phase 2a BEACON study in carriers of a pathogenic LRRK2 variant CAMBRIDGE, Mass. and SOUTH SAN FRANCISCO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) and Denali Therapeutics Inc. (NASDAQ:DNLI) today announced topline results from the Phase 2b LUMA study evaluating BIIB122 (DNL151), an investigational small molecule inhibitor of LRRK2 (leucine-rich repeat kinase 2), in indi
- PRBIIB SHAREHOLDER INVESTIGATION: SueWallSt Investigates Biogen Inc. for Possible Securities Law ViolationsBiogen Phase 2 CELIA trial data sent shares down 6.4% after it was revealed that topline data missed its primary endpoint.NEW YORK, May 18, 2026 /PRNewswire/ -- Biogen Inc. (NASDAQ:BIIB) shareholders lost 6.4% per share on May 14, 2026, when Phase 2 "CELIA" topline data for diranersen missed its primary dose-response endpoint. Investors who held BIIB through the drop are encouraged to submit their information to discuss their legal rights. You may also contact Joseph E. Levi, Esq. via email at jlevi@SueWallSt.com or by telephone at (888) SueWallSt. On May 14, Biogen released CEL
- ANALYSTEvercore ISI resumed coverage on BiogenEvercore ISI resumed coverage of Biogen with a rating of Outperform
- PRBiogen Completes Acquisition of Apellis PharmaceuticalsCAMBRIDGE, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) today announced the successful completion of the acquisition of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS). Apellis, a leader in advancing treatments for serious, complement-driven diseases, is now a wholly owned subsidiary of Biogen. The acquisition adds two best-in-class commercialized products, EMPAVELI® and SYFOVRE®, significantly bolstering Biogen's near-term growth outlook and accelerating the Company's expansion into nephrology. Together, the products recorded $689 million in net product revenue in 2025. This transaction will strengthen Biogen's revenue and EPS growth potential by being accretive to Bioge
- SECBiogen Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Regulation FD Disclosure, Financial Statements and Exhibits8-K - BIOGEN INC. (0000875045) (Filer)
- PRTopline Results from Phase 2 CELIA Study of Diranersen (BIIB080): First Study to Show Reduction in Tau Pathology and Cognitive Benefit in Patients with Early Alzheimer's DiseaseRobust reductions in tau pathology were observed across all studied doses, with results generally consistent with those observed in the Phase 1b study1Pre-specified analyses of cognitive endpoints demonstrated slowing of clinical decline across all studied doses, particularly at the lowest doseThe safety and tolerability profile of diranersen was generally consistent with the Phase 1b study1CELIA is an 18-month Phase 2 randomized, placebo-controlled, dose-ranging study evaluating diranersen, a tau-targeting antisense oligonucleotide (ASO)Data will be presented at the Alzheimer's Association International Conference (AAIC) 2026 and other upcoming scientific congresses CAMBRIDGE, Mass., May
- PRUpdate on FDA Priority Review of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection as a Starting Dose for Early Alzheimer's DiseaseTOKYO and CAMBRIDGE, Mass., May 08, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. and Biogen Inc. (NASDAQ:BIIB) today announced that the U.S. Food and Drug Administration (FDA) has extended the review period by three months for the supplemental Biologics License Application (sBLA) for a once-weekly lecanemab-irmb subcutaneous injection (U.S. brand name: LEQEMBI® IQLIK™) as a starting dose for the treatment of early Alzheimer's disease. The new Prescription Drug User Fee Act (PDUFA) action date is August 24, 2026. As part of the ongoing review process, the agency requested additional information and has determined that it constituted a major amendment to the sBLA, extending the PDUFA date to
- PRBright Horizons Family Solutions and Remitly Global Set to Join S&P SmallCap 600NEW YORK, May 7, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P SmallCap 600 effective prior to the opening of trading on Thursday, May 14: Bright Horizons Family Solutions Inc. (NYSE:BFAM) will replace Tri Pointe Homes Inc. (NYSE:TPH). Sumitomo Forestry Group (TSE: 1911) is acquiring Tri Pointe Homes in a deal expected to close soon, pending final closing conditions.Remitly Global Inc. (NASD: RELY) will replace Apellis Pharmaceuticals Inc. (NASD: APLS). S&P 500 constituent Biogen Inc. (NASD: BIIB) is acquiring Apellis Pharmaceuticals in a deal expected to close soon, pending final closing conditions.Following is a summary of the changes that will take
- PRStoke Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Updates– New 4-year longitudinal data from the Phase 1/2a open-label extension (OLE) studies provide additional support for the disease-modifying potential of zorevunersen, an investigational medicine for the treatment of Dravet syndrome – – Statistically significant improvements in cognition and behavior demonstrated at 1, 2, 3 and 4 years of treatment compared to OLE baseline, in addition to continued durability in seizure reductions – – Zorevunersen generally well tolerated, with some patients treated for more than 5 years – – Enrollment of approximately 150 patients into the Phase 3 EMPEROR study expected to complete in June 2026 to support a data readout in mid-2027; these data are anti
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Biogen Inc.SCHEDULE 13G/A - BIOGEN INC. (0000875045) (Subject)
- INSIDERHead of Corporate Development Keeney Adam converted options into 939 shares and covered exercise/tax liability with 455 shares, increasing direct ownership by 8% to 6,365 units (SEC Form 4)4 - BIOGEN INC. (0000875045) (Issuer)
- PRJeito Capital Bolsters Its Leadership Team With the Appointment of Elaine Caughey, MBA, as Partner, Business Development and Investor Relations, and Sarah Shackelton, MPA, as Partner, TalentHighly experienced partners bringing 25+ years of leadership across top-tier life-sciences investment fund, pharma and Biopharma companies, driving accelerated portfolio development With leadership experience at Blackstone Life Sciences (Deputy Chief Operating Officer), Biogen, (NASDAQ:BIIB), and public and private Biopharma companies (including Kymera Therapeutics (NASDAQ: KYMR) and Cygnal Therapeutics), Elaine Caughey will support portfolio companies in strengthening operational execution, defining robust market access pathways, and enhancing their strategic value through business development support, including partnerships and acquisition transactions. She will also draw on her know
- PRStoke Therapeutics to Host Webcast and Conference Call to Discuss First Quarter 2026 Business and Financial UpdatesStoke Therapeutics, Inc. (NASDAQ:STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced that management will host a webcast and conference call for analysts and investors on Thursday, May 7, 2026, at 4:30 p.m. ET, to discuss first quarter 2026 business and financial updates. The webcast will be available on the Investors & News section of Stoke's website at https://investor.stoketherapeutics.com/. Research analysts who plan to join the call a
- SECSEC Form 10-Q filed by Biogen Inc.10-Q - BIOGEN INC. (0000875045) (Filer)
- SECBiogen Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - BIOGEN INC. (0000875045) (Filer)
- SECSEC Form DEFA14A filed by Biogen Inc.DEFA14A - BIOGEN INC. (0000875045) (Filer)
- SECSEC Form DEF 14A filed by Biogen Inc.DEF 14A - BIOGEN INC. (0000875045) (Filer)
- FDAFDA Approval for ZURZUVAE issued to BIOGEN INCSubmission status for BIOGEN INC's drug ZURZUVAE (SUPPL-3) with active ingredient ZURANOLONE has changed to 'Approval' on 04/20/2026. Application Category: NDA, Application Number: 217369, Application Classification: Labeling
- ANALYSTBiogen upgraded by UBS with a new price targetUBS upgraded Biogen from Neutral to Buy and set a new price target of $225.00
BIIB FAQ
6 questionsWhat does Biogen Inc. do?
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic...Where does BIIB stock trade?
Biogen Inc. (BIIB) is listed on NASDAQ.What sector and industry is BIIB in?
Biogen Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.What are analysts saying about BIIB?
Biogen Inc. has had 8 recent analyst actions on file. The most recent action was from Evercore ISI: Outperform on 2026-05-15.What companies are similar to BIIB?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), SGEN (Seagen Inc.). Compare BIIB side-by-side with any of them on Quantisnow.How can I track BIIB on Quantisnow?
Quantisnow aggregates Biogen Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow BIIB to receive live email and push alerts on every new disclosure.